The global psoriasis treatment market size was estimated to be USD 29.16 billion in 2023 and is expected to reach at USD 77.87 billion by 2034 with a CAGR of 9.34% during the forecast period 2024-2034. Increasing prevalence of psoriasis along with skin disorders, growing awareness regarding treatments available in the market among population, rising focus on development of new biologics & novel pipeline drugs, surge in introduction of advanced biologics, increasing adoption of biological therapies for the treatment, and rising approvals of advanced products by regulatory bodies are some of the key factors boosting the market growth.
Rising approvals of advanced products by regulatory bodies is predicted to boost the market growth during the forecast period. Patients are searching for an effective treatment for psoriasis. The advent of biologics has transformed the way this condition is managed because they pinpoint specific aspects of the inflammatory process and come with fewer adverse effects. As a result, many significant players in the field have redirected their attention toward developing biologics. Developing biologics also comes with a streamlined approval process for new drugs. For instance, in May 2022, Dermavant Sciences has obtained approval from the United States Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist. It is indicated for the topical treatment of plaque psoriasis in adults. This endorsement establishes VTAMA cream as the initial and sole FDA-approved topical medication in its category that does not contain steroids.
By drug class, interleukin inhibitor was the highest revenue-grossing segment in the global psoriasis treatment market in 2023 owing to increasing prescription volume for the interleukin inhibitors, rising adoption of interleukin inhibitors by patient with psoriasis, surge in number of clinical trials being conducted, and growing approvals by regulatory bodies. For instance, in September 2022, Boehringer Ingelheim revealed that the U.S. Food and Drug Administration (FDA) granted approval to SPEVIGO, marking it as the initial sanctioned treatment for managing flare-ups of generalized pustular psoriasis (GPP) in adults. SPEVIGO is an innovative, specific antibody that obstructs the activation of the interleukin-36 receptor (IL-36R), a critical component of an immune system signaling pathway that has been associated with the underlying cause of GPP. Additionally, TNF-alpha inhibitors is predicted to grow at fastest CAGR during the forecast period owing to the improved safety & efficacy of TNF-alpha inhibitors, rising prevalence of autoimmune disorders, and growing approvals of advanced products by regulatory bodies.
By type, plaque psoriasis was the highest revenue-grossing segment in the global psoriasis treatment market in 2023 owing to the growing prevalence of plaque psoriasis, rising adoption of medication for the treatment of plaque psoriasis, and increasing regulatory approvals for new products. For instance, in June 2022, The US Food & Drug Administration (USFDA) has given Alembic Pharmaceuticals the green light to manufacture a generic edition of Clobetasol Propionate foam for treating plaque psoriasis. Additionally, psoriatic arthritis is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of biologics in the management of psoriatic arthritis and growing launch of innovative biological products by market players.
By route of administration, parenteral was the highest revenue-grossing segment in the global psoriasis treatment market in 2023 owing to the surge in launch of new drugs to be administered through injection or intravenous (IV) infusion, growing adoption of biologics for the treatment of psoriasis, and rising approvals of new drugs by regulatory bodies. For instance, in January 2022, AbbVie has been granted approval by the United States Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa), an inhibitor of interleukin-23 (IL-23), designed to treat active psoriatic arthritis (PsA) in adults. PsA is a systemic inflammatory condition that affects both the skin and joints and is prevalent in approximately 30% of individuals with psoriasis. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the rising introduction of novel oral drugs by major market players and increasing approvals by regulatory bodies.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, growing prevalence of psoriasis, increasing awareness initiatives regarding the disease among population, rising demand for effective treatment options for managing psoriasis, surge in research & development activities, and increasing approvals by U.S. FDA. For instance, in July 2022, Arcutis Biotherapeutics, Inc. has obtained approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) of ZORYVE (roflumilast) cream 0.3%. This medication is sanctioned for treating plaque psoriasis, including areas prone to skin-on-skin contact, in patients aged 12 years and older. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in the number of key players for manufacturing psoriasis products, rising prevalence of skin disease such as psoriasis, growing government initiatives to raise awareness among the population regarding psoriasis, and increasing launch of innovative products. For instance, in March 2023, Eli Lilly introduced Copellor (Ixekizumab) in the Indian market, targeting adults dealing with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy. Additionally, this medication will be accessible for adults facing active psoriatic arthritis.
Rising approvals of advanced products by regulatory bodies is predicted to boost the market growth during the forecast period. Patients are searching for an effective treatment for psoriasis. The advent of biologics has transformed the way this condition is managed because they pinpoint specific aspects of the inflammatory process and come with fewer adverse effects. As a result, many significant players in the field have redirected their attention toward developing biologics. Developing biologics also comes with a streamlined approval process for new drugs. For instance, in May 2022, Dermavant Sciences has obtained approval from the United States Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist. It is indicated for the topical treatment of plaque psoriasis in adults. This endorsement establishes VTAMA cream as the initial and sole FDA-approved topical medication in its category that does not contain steroids.
By drug class, interleukin inhibitor was the highest revenue-grossing segment in the global psoriasis treatment market in 2023 owing to increasing prescription volume for the interleukin inhibitors, rising adoption of interleukin inhibitors by patient with psoriasis, surge in number of clinical trials being conducted, and growing approvals by regulatory bodies. For instance, in September 2022, Boehringer Ingelheim revealed that the U.S. Food and Drug Administration (FDA) granted approval to SPEVIGO, marking it as the initial sanctioned treatment for managing flare-ups of generalized pustular psoriasis (GPP) in adults. SPEVIGO is an innovative, specific antibody that obstructs the activation of the interleukin-36 receptor (IL-36R), a critical component of an immune system signaling pathway that has been associated with the underlying cause of GPP. Additionally, TNF-alpha inhibitors is predicted to grow at fastest CAGR during the forecast period owing to the improved safety & efficacy of TNF-alpha inhibitors, rising prevalence of autoimmune disorders, and growing approvals of advanced products by regulatory bodies.
By type, plaque psoriasis was the highest revenue-grossing segment in the global psoriasis treatment market in 2023 owing to the growing prevalence of plaque psoriasis, rising adoption of medication for the treatment of plaque psoriasis, and increasing regulatory approvals for new products. For instance, in June 2022, The US Food & Drug Administration (USFDA) has given Alembic Pharmaceuticals the green light to manufacture a generic edition of Clobetasol Propionate foam for treating plaque psoriasis. Additionally, psoriatic arthritis is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of biologics in the management of psoriatic arthritis and growing launch of innovative biological products by market players.
By route of administration, parenteral was the highest revenue-grossing segment in the global psoriasis treatment market in 2023 owing to the surge in launch of new drugs to be administered through injection or intravenous (IV) infusion, growing adoption of biologics for the treatment of psoriasis, and rising approvals of new drugs by regulatory bodies. For instance, in January 2022, AbbVie has been granted approval by the United States Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa), an inhibitor of interleukin-23 (IL-23), designed to treat active psoriatic arthritis (PsA) in adults. PsA is a systemic inflammatory condition that affects both the skin and joints and is prevalent in approximately 30% of individuals with psoriasis. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the rising introduction of novel oral drugs by major market players and increasing approvals by regulatory bodies.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, growing prevalence of psoriasis, increasing awareness initiatives regarding the disease among population, rising demand for effective treatment options for managing psoriasis, surge in research & development activities, and increasing approvals by U.S. FDA. For instance, in July 2022, Arcutis Biotherapeutics, Inc. has obtained approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) of ZORYVE (roflumilast) cream 0.3%. This medication is sanctioned for treating plaque psoriasis, including areas prone to skin-on-skin contact, in patients aged 12 years and older. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in the number of key players for manufacturing psoriasis products, rising prevalence of skin disease such as psoriasis, growing government initiatives to raise awareness among the population regarding psoriasis, and increasing launch of innovative products. For instance, in March 2023, Eli Lilly introduced Copellor (Ixekizumab) in the Indian market, targeting adults dealing with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy. Additionally, this medication will be accessible for adults facing active psoriatic arthritis.
Segmentation: Psoriasis Treatment Market Report 2022 - 2033
Psoriasis Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- TNF-Alpha Inhibitors
- Interleukin Inhibitors
- Others
Psoriasis Treatment Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
Psoriasis Treatment Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Bn)
- Parenteral
- Oral
- Topical
Psoriasis Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Psoriasis Treatment Market: Drug Class Estimates & Trend Analysis
8. Psoriasis Treatment Market: Type Estimates & Trend Analysis
9. Psoriasis Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Psoriasis Treatment Market
12. Europe Global Psoriasis Treatment Market
13. Asia Pacific Global Psoriasis Treatment Market
14. Latin America Global Psoriasis Treatment Market
15. MEA Global Psoriasis Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Eli Lilly and Company
- Abbvie Inc.
- Novartis AG
- Boehringer Ingelheim
- Novan Inc. (EPI Health LLC)
- Amgen Inc.
- UCB S.A.
- Viatris Inc. (Mylan NV)
- Pfizer Inc.
- Bausch Health Companies Inc
- LEO Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 29.16 Billion |
| Forecasted Market Value ( USD | $ 77.87 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
